Float Short %

6.44

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

-0.05

EPS Last/This Y

0.45

EPS This/Next Y

0.25

Price

6.82

Target Price

7.58

Analyst Recom

1.5

Performance Q

41.87

Relative Volume

0.82

Beta

1.47

Ticker: ADPT

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	ADPT	5.99	0.32	0.01	1459
2024-12-20	ADPT	6.41	0.28	0.95	1619
2024-12-23	ADPT	6.31	0.33	0.50	1336
2024-12-24	ADPT	6.39	0.33	0.14	1338
2024-12-26	ADPT	6.45	0.33	0.04	1338
2024-12-27	ADPT	6.29	0.33	0.20	1354
2024-12-30	ADPT	6.1	0.33	0.03	1354
2024-12-31	ADPT	5.99	0.32	13.67	1384
2025-01-02	ADPT	6.18	0.32	0.00	1386
2025-01-03	ADPT	7.19	0.32	0.03	1388
2025-01-06	ADPT	7.01	0.26	0.00	1675
2025-01-07	ADPT	7.1	0.24	0.00	1809
2025-01-08	ADPT	6.69	0.22	1.00	1920
2025-01-09	ADPT	6.69	0.22	0.17	1920
2025-01-10	ADPT	6.49	0.22	0.20	1922
2025-01-13	ADPT	6.45	0.22	0.06	1910
2025-01-14	ADPT	6.07	0.21	0.40	2013
2025-01-15	ADPT	7.15	0.22	0.00	2019
2025-01-16	ADPT	6.95	0.22	0.79	2028
2025-01-17	ADPT	6.81	0.23	0.03	2062
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	ADPT	6.01	19.9	-	-1.11
2024-12-20	ADPT	6.41	19.9	-	-1.11
2024-12-23	ADPT	6.32	19.9	-	-1.11
2024-12-24	ADPT	6.39	19.9	-	-1.11
2024-12-26	ADPT	6.44	19.9	-	-1.11
2024-12-27	ADPT	6.30	19.9	-	-1.11
2024-12-30	ADPT	6.11	19.9	-	-1.11
2024-12-31	ADPT	5.99	19.9	-	-1.11
2025-01-02	ADPT	6.18	19.9	-	-1.11
2025-01-03	ADPT	7.19	19.9	-	-1.11
2025-01-06	ADPT	7.05	19.9	-	-1.11
2025-01-07	ADPT	7.11	19.9	-	-1.11
2025-01-08	ADPT	6.69	19.9	-	-1.11
2025-01-09	ADPT	6.69	19.9	-	-1.11
2025-01-10	ADPT	6.49	19.9	-	-1.11
2025-01-13	ADPT	6.45	19.9	-	-1.11
2025-01-14	ADPT	6.07	19.9	-	-1.11
2025-01-15	ADPT	7.16	19.9	-	-1.11
2025-01-16	ADPT	6.95	19.9	-	-1.11
2025-01-17	ADPT	6.82	19.9	-	-1.11
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	ADPT	-0.56	1.74	6.71
2024-12-20	ADPT	-0.56	1.74	6.71
2024-12-23	ADPT	-0.52	1.67	6.71
2024-12-24	ADPT	-0.52	1.67	6.71
2024-12-26	ADPT	-0.55	1.67	6.33
2024-12-27	ADPT	-0.56	1.67	6.33
2024-12-30	ADPT	-0.57	1.63	6.33
2024-12-31	ADPT	-0.57	1.63	6.33
2025-01-02	ADPT	-0.57	1.63	6.33
2025-01-03	ADPT	-0.56	1.63	6.33
2025-01-06	ADPT	-0.48	1.67	6.33
2025-01-07	ADPT	-0.48	1.67	6.33
2025-01-08	ADPT	-0.56	1.67	6.33
2025-01-09	ADPT	-0.56	1.67	6.33
2025-01-10	ADPT	-0.56	1.67	6.33
2025-01-13	ADPT	-0.56	1.68	6.44
2025-01-14	ADPT	-0.56	1.68	6.44
2025-01-15	ADPT	-0.56	1.68	6.44
2025-01-16	ADPT	-0.56	1.68	6.44
2025-01-17	ADPT	-0.56	1.68	6.44
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.22

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.27

Insider Transactions

-0.56

Institutional Transactions

1.68

Beta

1.47

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

90.4

Max Drawdown 5-Year %

-96.6

Target Price

7.58

P/E

Forward P/E

PEG

P/S

5.67

P/B

4.49

P/Free Cash Flow

EPS

-1.34

Average EPS Est. Cur. Y

-1.11

EPS Next Y. (Est.)

-0.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-110.13

Relative Volume

0.82

Return on Equity vs Sector %

-106.3

Return on Equity vs Industry %

-93.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.11

EBIT Estimation

Adaptive Biotechnologies Corpor

Sector: Healthcare

Industry: Biotechnology

Employees: 709

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

stock quote shares ADPT – Adaptive Biotechnologies Corporation Stock Price stock today

news today ADPT – Adaptive Biotechnologies Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ADPT – Adaptive Biotechnologies Corporation yahoo finance google finance

stock history ADPT – Adaptive Biotechnologies Corporation invest stock market

stock prices ADPT premarket after hours

ticker ADPT fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ADPT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y